Corvidia Stock

corvidiatx.comHealthcareFounded: 2015Funding to Date: $91.8MM

Corvidia Therapeutics is a developer of precision therapies using the science of genomics in new ways.

Register for Details

For more details on financing and valuation for Corvidia, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Corvidia.

Register Today


Management Team

Nicholas Coscia
GaoZhong Zhu
Vice President & Head of Pharmaceutical Development and Manufacturing
Marc de Garidel
Chief Executive Officer & Board Member
Matt Devalaraja Ph.D
Co-Founder, Executive Vice President & Head of Research & Development
Douglas Kling
Senior Vice President, Clinical Operations
Michael Davidson MD
Co-Founder, Board Member & Chief Scientific Officer
Ram Aiyar Ph.D
Co-Founder, Executive Vice President & Head of Business Development
Kurt Herzog
Senior Business Analyst

Board Members

Aaron Kantoff
Apple Tree Partners
Marc de Garidel
Sylvie Grégoire Ph.D
Graziano Seghezzi Ph.D
Sofinnova Partners
Michael Davidson MD
Karim Helmy Ph.D
Seth Harrison MD
Apple Tree Partners
Tyrell Rivers Ph.D

Other companies like Corvidia in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


/PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage company focused on the research, development and commercialization of transformative therapies in...
Corvidia Therapeutics, a Boston, MA-based biotechnology company focused on the development of precision cardiovascular therapies, raised $26m in Series A funding. The round was co-led by Sofinnova Partners and Apple Tree Partners. In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi, Partner at Sofinnova …